Massimo Cristofanilli, MD, FACP
@mcristofanill
Associate Director for Precision Medicine, Director of Breast Medical Oncology, Scientific Director Englander IPM @WeillCornell
ID: 483253162
04-02-2012 20:14:52
1,1K Tweet
2,2K Followers
1,1K Following
America's Best Hospitals: the 2024-2025 Honor Roll and Overview health.usnews.com/health-care/be… Congratulations to my colleagues for the recognition of excellence! @nyp Weill Cornell Medicine Herbert Irving Comprehensive Cancer Center Weill Cornell Medicine Meyer Cancer Center
Congratulations to a junior rising star! Weill Cornell Medicine Meyer Cancer Center Weill Cornell Medicine WCM Englander Institute for Precision Medicine
Excellent example of combination of clinical and molecular data to predict activity of targeted single agent in HR+ MBC. International Society of Liquid Biopsy WCM Englander Institute for Precision Medicine #MBC
Moving ctDNA to for early detection of solid tumors is becoming a reality and will change the screening for populations and high risk individuals International Society of Liquid Biopsy WCM Englander Institute for Precision Medicine reuters.com/business/healt…
The journey that changed cancer diagnostics: vision, research, clinical application. WCM Englander Institute for Precision Medicine Weill Cornell Medicine Meyer Cancer Center International Society of Liquid Biopsy AACR Weill Cornell Medicine Meyer Cancer Center NewYork-Presbyterian ASCO
Starting Now: Inflammatory Breast Cancer Moderated by: Massimo Cristofanilli, MD, FACP Weill Cornell Medicine #DAVABreast
Circulating Tumor DNA and Survival in Metastatic Breast Cancer jamanetwork.com/journals/jaman… WCM Englander Institute for Precision Medicine International Society of Liquid Biopsy Weill Cornell Medicine Meyer Cancer Center
Guardant Health, Inc. - Guardant Health and Policlinico Gemelli Announce Partnership to Establish A Dedicated In-House Liquid Biopsy Testing Service in Italy. International Society of Liquid Biopsy investors.guardanthealth.com/press-releases…
KN-522 trial shows promising results in TNBC (Stage II-III)! Pembrolizumab + Chemo improves EFS and OS. A new SoC for #TNBC. 💪 @oncoalert ESMO - Eur. Oncology #cancer #oncology #ESMO24 Toni Choueiri, MD Evandro de Azambuja, MD, PhD Andres Cervantes FabriceAndre
Exploring the additional prognostic value of CTCs count in predicting site -specific metastatic behavior. International Society of Liquid Biopsy #mbc WCM Englander Institute for Precision Medicine Cristofanilli CTC Laboratory
Increasing and persistent benefit of the combination nivolumab-Ipilimumab suggesting achieved cure in advanced melanoma. Weill Cornell Medicine Meyer Cancer Center Weill Department of Medicine
Liquid biopsy provides new insights into the clinical and biological behavior of IBC in real-time in the unique environment of the IBC patient. Cristofanilli CTC Laboratory International Society of Liquid Biopsy IBCIC Wendy Woodward MDPhD